roschetzkyistockphoto

roschetzky / iStockphoto

21 August 2017Americas

J&J handed reprieve over ‘potentially deadly’ counterfeits

Johnson & Johnson (J&J) has been handed another victory in its fight against counterfeits after being granted an injunction preventing several companies from selling “potentially deadly” versions of a blood glucose strip it produces.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages